JP2023529485A5 - - Google Patents
Info
- Publication number
- JP2023529485A5 JP2023529485A5 JP2022576447A JP2022576447A JP2023529485A5 JP 2023529485 A5 JP2023529485 A5 JP 2023529485A5 JP 2022576447 A JP2022576447 A JP 2022576447A JP 2022576447 A JP2022576447 A JP 2022576447A JP 2023529485 A5 JP2023529485 A5 JP 2023529485A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- combination according
- combination
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038856P | 2020-06-14 | 2020-06-14 | |
| US63/038,856 | 2020-06-14 | ||
| US202063060605P | 2020-08-03 | 2020-08-03 | |
| US63/060,605 | 2020-08-03 | ||
| US202063198856P | 2020-11-17 | 2020-11-17 | |
| US63/198,856 | 2020-11-17 | ||
| PCT/US2021/036992 WO2021257398A1 (en) | 2020-06-14 | 2021-06-11 | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529485A JP2023529485A (ja) | 2023-07-10 |
| JP2023529485A5 true JP2023529485A5 (enExample) | 2024-06-06 |
Family
ID=76731129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576447A Pending JP2023529485A (ja) | 2020-06-14 | 2021-06-11 | Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230218649A1 (enExample) |
| EP (1) | EP4164655A1 (enExample) |
| JP (1) | JP2023529485A (enExample) |
| KR (1) | KR20230024402A (enExample) |
| CN (1) | CN116033907A (enExample) |
| AU (1) | AU2021292458A1 (enExample) |
| BR (1) | BR112022025480A2 (enExample) |
| CA (1) | CA3181278A1 (enExample) |
| IL (1) | IL298977A (enExample) |
| MX (1) | MX2022015894A (enExample) |
| WO (1) | WO2021257398A1 (enExample) |
| ZA (1) | ZA202213322B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250100273A (ko) * | 2023-12-26 | 2025-07-03 | 서울대학교병원 | 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2264043T3 (pl) | 2005-09-02 | 2018-04-30 | Glycomimetics, Inc. | Heterobifunkcyjne inhibitory pan-selektyny |
| WO2009073911A1 (en) | 2007-12-10 | 2009-06-18 | Mater Medical Research Institute | Treatment and prophylaxis |
| CA2760292A1 (en) | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| KR102055958B1 (ko) * | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
| WO2015048616A1 (en) * | 2013-09-30 | 2015-04-02 | Glycomimetics, Inc. | Methods and compositions for treating and/or preventing mucositis |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| US20200171005A9 (en) | 2015-12-02 | 2020-06-04 | Glycomimetics, Inc. | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker |
| AU2017341065B2 (en) | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
| JP7275131B2 (ja) * | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| KR20200128025A (ko) * | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2020219419A1 (en) | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Multimeric pan–selectin antagonists |
| JP2022529806A (ja) | 2019-04-24 | 2022-06-24 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤 |
| US20220265691A1 (en) | 2019-07-12 | 2022-08-25 | Glycomimetics, Inc. | Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types |
-
2021
- 2021-06-11 AU AU2021292458A patent/AU2021292458A1/en not_active Abandoned
- 2021-06-11 CA CA3181278A patent/CA3181278A1/en active Pending
- 2021-06-11 US US18/001,614 patent/US20230218649A1/en active Pending
- 2021-06-11 IL IL298977A patent/IL298977A/en unknown
- 2021-06-11 WO PCT/US2021/036992 patent/WO2021257398A1/en not_active Ceased
- 2021-06-11 CN CN202180056345.7A patent/CN116033907A/zh active Pending
- 2021-06-11 KR KR1020237001653A patent/KR20230024402A/ko active Pending
- 2021-06-11 MX MX2022015894A patent/MX2022015894A/es unknown
- 2021-06-11 JP JP2022576447A patent/JP2023529485A/ja active Pending
- 2021-06-11 EP EP21736926.3A patent/EP4164655A1/en active Pending
- 2021-06-11 BR BR112022025480A patent/BR112022025480A2/pt not_active Application Discontinuation
-
2022
- 2022-12-08 ZA ZA2022/13322A patent/ZA202213322B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6063628B2 (ja) | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 | |
| Li et al. | Advancements in conventional cancer therapy combined with immunotherapy | |
| Tsuboi et al. | A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia | |
| Wang et al. | Pancytopenia and severe gastrointestinal toxicities associated with 5-fluorouracil in a patient with thymidylate synthase (TYMS) polymorphism | |
| Hoskin et al. | Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix | |
| JP2024524461A (ja) | 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療 | |
| Ryu et al. | C‑C motif chemokine receptors in gastric cancer | |
| JP2023529485A5 (enExample) | ||
| ES2389809T3 (es) | Terapias anticancerosas | |
| JP2016501208A (ja) | ボラセルチブとの併用療法 | |
| WO2020236667A1 (en) | Methods of treating cancer | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| Okosun et al. | EZH2 gain‐of‐function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma (FL): a preliminary analysis on 590 patients | |
| US20240091183A1 (en) | Treatment regimens with fixed doses of tamibarotene | |
| US20180133192A1 (en) | Fructose analogs and their combinations as anti-cancer agents | |
| Su et al. | Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro | |
| Leonhardt et al. | Achievement of Clinical Remission in Life-Threatening Rosai-Dorfman Disease With Cladribine. | |
| Jansen et al. | Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD‐1 inhibitors | |
| Li et al. | PR064/# 206 Multicenter real-world experiences of PARPi rechallenge in patients with ovarian cancer in China | |
| Pensabene et al. | LGG-46. MEKI WITH MIRDAMETINIB: EXPLORING ADAPTIVE SIGNALING PATHWAY DYNAMICS AND IMMUNE MODULATION IN PEDIATRIC GLIOMAS | |
| Gambardella et al. | In the literature: July 2023. | |
| Zygmunciak et al. | Ruxolitinib as a primary treatment for multiple myeloma in a patient with primary myelofibrosis? A case report and the review of the literature | |
| Wei et al. | Jiaxin Ren1, 2, Ling Gu2 and Xue Tang2, 3 | |
| Brændstrup et al. | Concomitant Langerhans Cell Histiocytosis and Chronic Myelomonocytic Leukaemia Responding to 5-azacitidine | |
| Karschnia et al. | JS05. 7. A SURGICAL RE-RESECTION FOR RECURRENT GLIOBLASTOMA: PROGNOSTIC EVALUATION USING THE NOVEL RANO CLASSIFICATION FOR EXTENT OF RESECTION FROM THE RANO RESECT GROUP |